ACIU supply chain intelligence for AC Immune SA: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
AC Immune SA (ACIU) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JANSSEN-PHARMACEUTICALS-INC | JANSSEN-PHARMACEUTICALS-INC | 92% | We are in a partnership with Janssen to develop and commercialize therapeutic anti-Tau active immunotherapies for the treatment of AD and potentially other tauopathies. |
| LANTHEUS-HOLDINGS-INC | LANTHEUS-HOLDINGS-INC | 92% | We also have a diagnostic partnership with Lantheus for compounds, which bind pathological Tau for use as a PET tracer. |
| LLY | Eli Lilly and Company | 92% | Reciprocal relationship from LLY graph: Reciprocal relationship from ACIU graph: ave achieved and our goal of a close working relationship with the regulatory agencies, in particular the FDA, are int… |
| LLY | Eli Lilly and Company | 92% | ave achieved and our goal of a close working relationship with the regulatory agencies, in particular the FDA, are intended to facilitate expeditious execution through the regulatory approval process… |
| TAKEDA-PHARMACEUTICALS-USA-INC | TAKEDA-PHARMACEUTICALS-USA-INC | 92% | In May 2024, we entered into a worldwide option and license agreement with Takeda for our active immunotherapies targeting Abeta, including ACI-24.060. |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ACIU graph: ave achieved and our goal of a close … |
| JNJ | Johnson & Johnson | 72% | ave achieved and our goal of a close working relationship with the regulatory agencies, in particular the FDA, are intended to facilitate expeditious execution through the regulatory approval process… |
| LNTH | Lantheus Holdings, Inc. | 72% | Reciprocal relationship from LNTH graph: Item 1A. “Risk Factors” of this Form 10-K for information regarding certain risks associated with our raw materials and supply arrangements. Manufacturing The… |
| TAK | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TAK graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from TAK graph: 16,363 ) Reclassification adjustments to profit or (loss) 9,118 16,150 16,363 … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JNJ | Johnson & Johnson | 72% | discussed below). Further, the Civil Monetary Penalties Law imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim … |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from JNJ grap… |
| LLY | Eli Lilly and Company | 72% | g the years ended December 31, 2019 and 2018, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods … |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from LLY grap… |
| LNTH | Lantheus Holdings, Inc. | 72% | opean Union have imposed certain sanctions against Russia. The invasion of Ukraine and the retaliatory measures that have been taken, or could be taken in the future, by the United States, NATO, and … |
| LNTH | Lantheus Holdings, Inc. | 72% | Reciprocal relationship from LNTH graph: Item 1A. “Risk Factors” of this Form 10-K for information regarding certain risks associated with our raw materials and supply arrangements. Manufacturing The… |
| SNYNF | Sanofi | 72% | n penetrant small molecule inhibitors of NLRP3 inflammasome activation for the treatment of PD. In February 2023, the Company announced that it had been awarded a new grant totaling USD 0.5 (CHF 0.4)… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ACIU graph: n penetrant small molecule inhibitors of NLRP3 inflammasome activation for the treatment of PD. In February 2023, th… |
| AC-IMMUNE-USA-INC | AC-IMMUNE-USA-INC | 62% | scussed below). Further, the Civil Monetary Penalties Law imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to… |
| CGEN | Compugen Ltd. | 62% | Reciprocal relationship from CGEN graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from CGEN graph: Reciprocal relationship from ACIU graph: scussed below). Further, the Civil … |
| COGENCY-GLOBAL-INC | COGENCY-GLOBAL-INC | 62% | scussed below). Further, the Civil Monetary Penalties Law imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to… |
| JANSSEN-PHARMACEUTICALS-INC | JANSSEN-PHARMACEUTICALS-INC | 62% | ndidates with desired cerebrospinal fluid exposure and selectivity for pathological aggregated Tau. These will be broadly developed in Tau-dependent neurodegenerative diseases by Lilly. Lilly is resp… |
| MRK | Merck & Co., Inc. | 62% | Reciprocal relationship from MRK graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from MRK graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from MRK grap… |
| ROCHE-GROUP | ROCHE-GROUP | 62% | scussed below). Further, the Civil Monetary Penalties Law imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to… |
| TAK | Takeda Pharmaceutical Company Limited | 62% | Reciprocal relationship from TAK graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from TAK graph: Reciprocal relationship from ACIU graph: Reciprocal relationship from TAK grap… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ACIU-DEBT | Debt stack $5.5M | 90% | Market cache reports total debt of $5.5M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ACIU-OWNER-BVF-INC-IL | BVF INC/IL | 90% | 13F overlay lists BVF INC/IL as top holder; 47 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| TEVJF | Teva Pharmaceutical Industries Limited | 100.00 | 2 | |
| GIFOF | Grifols, S.A. | 100.00 | 2 | |
| TAK | Takeda Pharmaceutical Company Limited | 100.00 | 1 | ['customer', 'supplier'] |
| JNJ | Johnson & Johnson | 100.00 | 1 | ['customer', 'supplier'] |
| SNNUF | Smith & Nephew plc | 100.00 | 2 | |
| GRFS | Grifols, S.A. | 100.00 | 2 | |
| GIKLY | Grifols, S.A. | 100.00 | 2 | |
| SNYNF | Sanofi | 100.00 | 1 | ['customer'] |
| LLY | Eli Lilly and Company | 100.00 | 1 | ['customer', 'supplier'] |
| LNTH | Lantheus Holdings, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 | |
| AORT | Artivion, Inc. | 50.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 50.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 50.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 50.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 50.00 | 2 | |
| BLLN | BillionToOne, Inc. | 50.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 50.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 50.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 50.00 | 2 |